Contract facts
FederalNo full NAICS 561210 intel page yet. Browse NAICS intelligence
RETROSPECTIVE TUMOR CHARACTERIZATION ANALYSIS (MOONSHOT) is a federal award for Nih Nci held by Leidos Biomedical Research, Inc. Estimated value $21.3M ($-1,500,003 obligated). Current period of performance ends Sep 30, 2026. Place of performance: FREDERICK MD. Related solicitation N01CO5240180.
RETROSPECTIVE TUMOR CHARACTERIZATION ANALYSIS (MOONSHOT)
Recompete timing
PublicCurrent PoP ends Sep 30, 2026 (41 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordLeidos Biomedical Research, Inc — $2.1B obligated across 186 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HHSN26100039?
HHSN26100039 (Retrospective TUMOR characterization analysis) is a Nih Nci award with a potential value of $21.3M, currently held by Leidos Biomedical Research, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded HHSN26100039?
Nih Nci awarded HHSN26100039 to Leidos Biomedical Research, Inc (potential $21.3M).
Who is the incumbent on HHSN26100039?
Leidos Biomedical Research, Inc is the incumbent with $2.1B across 186 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.
When does Leidos Biomedical Research, Inc’s HHSN26100039 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.